Zhang Financial LLC grew its position in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA – Free Report) by 34.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 93,187 shares of the company’s stock after purchasing an additional 23,800 shares during the quarter. Zhang Financial LLC’s holdings in Tiziana Life Sciences were worth $65,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, Sanctuary Advisors LLC bought a new stake in Tiziana Life Sciences in the 3rd quarter valued at about $864,000.
Tiziana Life Sciences Trading Down 2.6 %
Shares of NASDAQ:TLSA opened at $0.74 on Tuesday. The company has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $0.95. Tiziana Life Sciences Ltd has a twelve month low of $0.41 and a twelve month high of $1.74.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Featured Articles
- Five stocks we like better than Tiziana Life Sciences
- Using the MarketBeat Stock Split Calculator
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- What Investors Need to Know to Beat the Market
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Want to see what other hedge funds are holding TLSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tiziana Life Sciences Ltd (NASDAQ:TLSA – Free Report).
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.